Codexis to Report First Quarter 2026 Financial Results on May 7
Codexis (NASDAQ: CDXS) will report Q1 2026 financial results on May 7, 2026 after market close.
Rhea-AI Summary
Codexis (NASDAQ: CDXS) will report Q1 2026 financial results on May 7, 2026 after market close. Management will host a conference call and webcast at 4:30 PM ET to discuss results and provide a business update. The live webcast will be archived for 90 days; telephone replay available for 48 hours (Access ID #13726635).
Positive
- None.
Negative
- None.
Details
News Market Reaction – CDXS
In the Apr 23 session, CDXS gained 2.02%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Earnings date
- May 7, 2026
- Scheduled Q1 2026 financial results release after market close
- Earnings call time
- 4:30 pm Eastern Time
- Start time of Q1 2026 results conference call and webcast
- Webcast archive period
- 90 days
- Period Codexis will archive the Q1 2026 webcast on its IR site
- Replay availability
- 48 hours
- Telephone replay window for the Q1 2026 earnings call
- Domestic dial-in
- 877-705-2976
- U.S. access number for the live Q1 2026 earnings call
- Replay access ID
- 13726635
- Access code required to listen to the Q1 2026 replay
Previous Earnings date Reports
-
Scheduled Q4 and FY2025 results call on March 11 with webcast details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the first quarter of 2026 on Thursday, May 7, 2026, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.
Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis® manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
For More Information
Investor Contact
Georgia Erbez
(650) 421-8100
ir@codexis.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.